Skip to main content
SpringerLink
Log in

Validation of the 7th Edition TNM Staging System for Hepatocellular Carcinoma: An Analysis of 8,828 Patients in a Single Medical Center

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Major modification of the 7th tumor-node-metastasis (TNM) staging system for hepatocellular carcinoma (HCC) was divided into 6th stage IIIA to 7th IIIA (multiple tumors, any >5 cm) and IIIB (tumors involving a major vessel). This study aimed to validate 6th and 7th TNM systems in prognostic prediction, then analyze the impact of time, Child-Pugh classification and treatment modalities in survival.

Methods

A total of 5,611 and 3,217 HCC patients were enrolled between 1986–2002 (past period) and 2003–2010 (recent period), respectively. The Akaike information criteria (AIC) within a Cox proportional hazard regression model were used to demonstrate the discriminatory ability for staging systems.

Results

The 1-, 3-, and 5-year survival rates of past and recent periods were 44.8, 24.9, 17.1 %, and 65.5, 44.5, 34.6 %, respectively (p < 0.001). Rates of smaller HCC detection and received curative treatment were significantly higher in the recent period than in the past period (p < 0.001). Survival rates were different in each Child-Pugh class (all p < 0.001). Patients receiving curative treatment had highest survival rates, followed by non-curative treatment, and untreated patients (p < 0.05). In both periods, significant differences in survival curves existed between each of the stages in the 6th and 7th TNM staging (all p < 0.05), and also between IIIA and IIIB in the 7th TNM (p < 0.001). The AIC of two periods in the 6th and 7th TNM systems were decreased, with 77,895 and 77,630, and 19,162 and 19,135, respectively.

Conclusion

The 7th TNM provided better prognostic prediction than the 6th TNM after dividing into IIIA and IIIB. Survival rates of HCC have been improving in recent decades.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.

    Article  PubMed  CAS  Google Scholar 

  2. Department of Health, Taiwan. (2008) 2008 statistics of causes of death. Available from http://www.doh.gov.tw/EN2006/DM/DM2.aspx?now_fod_list_no=10864&class_no=390&level_no=2. Cited 29 June 2011.

  3. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. 6th ed. Chicago: Springer; 2002.

    Book  Google Scholar 

  4. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928.

    Article  PubMed  CAS  Google Scholar 

  5. [No authors listed] (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–755.

    Google Scholar 

  6. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–215.

    Article  PubMed  Google Scholar 

  7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338.

    Article  PubMed  CAS  Google Scholar 

  8. Omagari K, Honda S, Kadokawa Y, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19:805–811.

    Article  PubMed  Google Scholar 

  9. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419–425.

    Article  PubMed  CAS  Google Scholar 

  10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. Springer: New York; 2010:191–200.

    Google Scholar 

  11. Kee KM, Wang JH, Lee CM, et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650–2655.

    Article  PubMed  CAS  Google Scholar 

  12. Cheng CH, Lee CF, Wu TH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114.

    Article  PubMed  Google Scholar 

  13. Xu LB, Wang J, Liu C, et al. Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. World J Gastroenterol. 2010;16:5257–5262.

    Article  PubMed  Google Scholar 

  14. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.

    Article  PubMed  Google Scholar 

  15. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001;34:529–534.

    Article  PubMed  CAS  Google Scholar 

  16. Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Wiley: Chichester; 1998:123–124.

    Google Scholar 

  17. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708–2716.

    Article  PubMed  Google Scholar 

  18. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720–727.

    PubMed  CAS  Google Scholar 

  19. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–460.

    Article  PubMed  CAS  Google Scholar 

  20. Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 2003;237:376–383.

    PubMed  Google Scholar 

  21. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197:753–758.

    Article  PubMed  Google Scholar 

  22. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228:479–490.

    Article  PubMed  CAS  Google Scholar 

  23. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–967.

    Article  PubMed  Google Scholar 

  24. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–1086.

    Article  PubMed  CAS  Google Scholar 

  25. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086–1092.

    Article  PubMed  Google Scholar 

  26. Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000;127:603–608.

    Article  PubMed  CAS  Google Scholar 

  27. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986;90:263–267.

    PubMed  CAS  Google Scholar 

  28. Kee KM, Lu SN. Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology. 2011;81:36–40.

    Article  PubMed  Google Scholar 

  29. Huang YC, Huang CF, Chang KC, et al. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol. 2011;26:129–134.

    Article  PubMed  Google Scholar 

  30. Tseng PL, Wang JH, Tung HD, et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426–1434.

    Article  PubMed  CAS  Google Scholar 

  31. Lin CY, Kee KM, Wang JH, et al. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74–81.

    Article  PubMed  Google Scholar 

  32. Changchien CS, Chen CL, Yen YH, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159–170.

    Article  PubMed  CAS  Google Scholar 

  33. Yen YH, Changchien CS, Wang JH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009;41:431–441.

    Article  PubMed  Google Scholar 

  34. Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma—survival analysis of 3892 patients. Eur J Cancer. 2008;44:1000–1006.

    Article  PubMed  Google Scholar 

  35. Chen CH, Su WW, Yang SS, et al. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol. 2006;21:1561–1566.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung District, Kaohsiung, 833, Taiwan

    Kwong-Ming Kee, Jing-Houng Wang, Chih-Yun Lin & Sheng-Nan Lu

  2. Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan

    Chih-Chi Wang

  3. Department of Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan

    Yu-Fan Cheng

Authors
  1. Kwong-Ming Kee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing-Houng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chih-Yun Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chih-Chi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Fan Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheng-Nan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheng-Nan Lu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kee, KM., Wang, JH., Lin, CY. et al. Validation of the 7th Edition TNM Staging System for Hepatocellular Carcinoma: An Analysis of 8,828 Patients in a Single Medical Center. Dig Dis Sci 58, 2721–2728 (2013). https://doi.org/10.1007/s10620-013-2716-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-013-2716-8

Keywords

Search

Navigation